← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. UTHR
  3. P/E History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargets

UTHR logoUnited Therapeutics Corporation (UTHR) P/E Ratio History

Historical price-to-earnings valuation from 2004 to 2026

Current P/E
21.4
Overvalued
5Y Avg P/E
15.3
+40% vs avg
PE Percentile
90%
High
PEG Ratio
1.11
Fair
TTM EPS$27.28
Price$596.13
5Y PE Range10.9 - 21.9
Earnings Yield4.67%

Loading P/E history...

UTHR Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
21.4vs15.3
+40%
Premium vs History
vs. Healthcare
21.4vs22.1
-3%
In Line with Sector
vs. S&P 500
21.4vs25.2
-15%
Below Market
PEG Analysis
1.11
P/E ÷ EPS Growth
PEG 1-2 = Fair
Based on 13% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 7, 2026, United Therapeutics Corporation (UTHR) trades at a price-to-earnings ratio of 21.4x, with a stock price of $596.13 and trailing twelve-month earnings per share of $27.28.

The current P/E is 40% above its 5-year average of 15.3x. Over the past five years, UTHR's P/E has ranged from a low of 10.9x to a high of 21.9x, placing the current valuation at the 90th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, UTHR is roughly in line with its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.

The PEG ratio of 1.11 (P/E divided by 13% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, UTHR trades roughly in line with the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our UTHR DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

UTHR P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ACAD logoACADACADIA Pharmaceuticals Inc.
$4B9.4-+68%
INVA logoINVAInnoviva, Inc.
$2B6.8Lowest0.66Best+817%Best
HALO logoHALOHalozyme Therapeutics, Inc.
$8B25.91.13-25%
MNKD logoMNKDMannKind Corporation
$1B178.0--79%
LNTH logoLNTHLantheus Holdings, Inc.
$6B25.3--22%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

UTHR Historical P/E Data (2004–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2026 Q1$592.87$27.0521.9x-19%
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$487.25$27.8617.5x-35%
FY2025 Q3$419.21$26.3915.9x-41%
FY2025 Q2Mon Jun 30 2025 00:00:00 GM$287.35$25.6211.2x-58%
FY2025 Q1Mon Mar 31 2025 00:00:00 GM$308.27$25.0612.3x-54%
FY2024 Q4$352.84$24.6014.3x-47%
FY2024 Q3Mon Sep 30 2024 00:00:00 GM$358.35$22.7715.7x-41%
FY2024 Q2Sun Jun 30 2024 00:00:00 GM$318.55$21.7614.6x-46%
FY2024 Q1Sun Mar 31 2024 00:00:00 GM$229.72$21.1510.9x-60%
FY2023 Q4Sun Dec 31 2023 00:00:00 GM$219.89$19.8411.1x-59%
FY2023 Q3Sat Sep 30 2023 00:00:00 GM$225.87$18.1512.4x-54%
FY2023 Q2Fri Jun 30 2023 00:00:00 GM$220.75$17.6812.5x-54%

Average P/E for displayed period: 26.9x

Full UTHR Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

See UTHR's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is UTHR Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare UTHR vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

UTHR — Frequently Asked Questions

Quick answers to the most common questions about buying UTHR stock.

Is UTHR stock overvalued or undervalued?

UTHR trades at 21.4x P/E, above its 5-year average of 15.3x. The 90th percentile ranking indicates a premium to historical valuation.

How does UTHR's valuation compare to peers?

United Therapeutics Corporation P/E of 21.4x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.

What is UTHR's PEG ratio?

UTHR PEG ratio is 1.11. Between 1-2 suggests valuation aligns with growth. Historical P/E data spans 2004-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

UTHR P/E Ratio History (2004–2026)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.